若生智能
Drug Database
TR

travoprost (Travatan Z / Travantan Z / Travatanz)

✓ Approved

Novartis AG · PTGFR · 小分子

什么是 travoprost？

travoprost 是一种小分子，由Novartis AG研发。该药已获批，用于治疗相关适应症，给药途径：Others。

药物档案

商品名Travatan Z, Travantan Z, Travatanz
公司Novartis AG
药物类别小分子
分子靶点PTGFR
给药途径Others
状态Approved
来源： ClinicalTrials.gov, Novartis AG

作用机制

分子靶点

travoprost 作用于 1 个分子靶点：

PTGFRprostaglandin F receptor (FP)
需要更深入的分析？Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

travoprost 针对 1 个适应症，涉及 1 个治疗领域。

治疗领域疾病/病症分期
Eye disordersGlaucoma✓ Approved

相关研究文献

PubMedJournal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics2026-08-03

Sustained-Release Intracameral Prostaglandin Analog Implants for Glaucoma: Comparative Review and Meta-Analysis of Bimatoprost and Travoprost Delivery Systems.

Chopra Alexander L AL, Siringoringo Clyde C, Siu Sharmayne S, Francis Brian B et al.

To evaluate the efficacy and safety of sustained-release intracameral prostaglandin analog implants, including bimatoprost (Durysta) and travoprost (iDose TR), in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT). A systematic review and pooled quantitative analysis were performed according to PRISMA guidelines. PubMed, Scopus, Embase, and Google Scholar were searched for studies published between 2020 and 2025 evaluating sustained-release intracameral prostaglandin implants. Randomized and nonrandomized studies reporting intraocular pressure (IOP) and safety outcomes were included. Six studies comprising 1,047 eyes met inclusion criteria. Bimatoprost implants (10 µg and 15 µg) achieved mean IOP reductions of 6.1-6.7 mmHg at 12 months, whereas pooled slow-eluting travoprost implant data demonstrated reductions ranging from 5.5 to 7.75 mmHg depending on study design and follow-up duration. Subgroup analysis demonstrated comparable efficacy between travoprost and bimatoprost implants at 3 months; however, at 12 months, travoprost efficacy was lower than the 15 µg bimatoprost implant while remaining comparable to the 10 µg implant. Most adverse events were mild and transient. Corneal endothelial cell loss occurred in a dose-dependent manner with repeated bimatoprost administrations, particularly with the 15 µg implant, whereas no significant endothelial cell loss was reported with travoprost implants. Both implants substantially reduced topical medication burden. Sustained-release intracameral prostaglandin implants provide durable IOP reduction while decreasing dependence on topical therapy. Although efficacy differences between travoprost and bimatoprost implants appear modest, their safety profiles differ, particularly regarding corneal endothelial effects. Further long-term comparative studies are warranted.

PMID 42544565
阅读全文 →
PubMedJournal of oleo science2026-08-03

Synthesis and Mesomorphic Properties of Acyclic Amines with 5-Alkoxytropon-2-yl Groups.

Kubo Kanji K, Yamamoto Emi E, Ujiie Seiji S, Mori Akira A

Liquid‑crystalline compounds with 5‑alkoxytropon‑2‑yl groups were synthesized from acyclic amines such as tris(2‑aminoethyl)amine, 1,5‑diaminopentane, bis(2‑aminoethyl)ether, diethylenetriamine, and N‑(3‑aminopropyl)‑1,3‑propanediamine. All of the acyclic amines functionalized with 5‑alkoxytropon‑2‑yl groups exhibited the SmA phase. The POM and XRD analyses revealed that these compounds possess a high degree of self‑orienting ability and adopt a homeotropic alignment in the SmA phase.

PMID 42543622
阅读全文 →
PubMedFitoterapia2026-08-03

Vicenin-2 alleviates oxidative stress in HT22 cells and Caenorhabditis elegans as a potential KEAP1-NRF2 interaction inhibitor.

Liang Yu-Wen YW, Liang Xiao-Lu XL, Mo Fei-Fan FF, Tian Jing J et al.

Flavone C-glycosides are a class of compounds characterized by glycosyl moieties directly bonded to the flavone skeleton via CC linkages, predominantly on the C-6 and C-8 positions of the A-ring. Vicenin-2, a 6,8-di-C-glycoside derived from apigenin, is widely present in some dietary sources such as juice, herbal teas and stewed soups. While its antioxidant potential is recognized, the molecular mechanisms underlying its protective effects against oxidative stress remain poorly explored. Given the vicious cycle between oxidative stress and neurotoxicity, this study investigated the protective efficacy and molecular mechanisms of vicenin-2 against t-Butyl Hydroperoxide (tBHP)-challenged Caenorhabditis elegans and H₂O₂-induced HT22 neuronal cells. Molecular docking and dynamics simulation revealed that vicenin-2 disrupts the binding of KEAP1 and NRF2. Both in vitro and in vivo assay demonstrated treatment of vicenin-2 activated the antioxidant system, and qPCR and Western blot results confirmed the KEAP1-NRF2-HO-1 pathway as central to its activities. Computational-experimental synergy unveils vicenin-2 as a KEAP1-NRF2 protein-protein interaction inhibitor. Our findings highlight the potential of vicenin-2 for oxidative stress conditions, and position vicenin-2 as a promising neuroprotective therapeutic candidate although more mammal experimental evidence is warranted.

PMID 42543089
阅读全文 →
PubMedZhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica2026-08-03

[Prenylated flavonoids from Sophorae Tonkinensis Radix et Rhizoma and their cytotoxic activities].

Tang Feng-Jiao FJ, Yin Jing-Hui JH, Zou Wei W, Long Fang F et al.

Comprehensive chromatographic separation methods were employed to isolate and purify the chemical constituents from the non-alkaloidal fraction of Sophorae Tonkinensis Radix et Rhizoma, and the structures of the compounds were identified with mass spectrometry(MS) and nuclear magnetic resonance(NMR) data. Fourteen prenylated flavonoids were isolated and identified, namely 5-isopentenylsophotonin Ⅰ(1),(2S)-6-isopentenyl-2'-hydroxyglabrol(2), sophoradin(3), sophoradochromene(4), 1-prenylpterocarpin(5), sophoranone(6), glabrol(7), 7,4'-dihydroxy-6,8-diprenyldihydroflavone(8), isobavachin(9), sophoranochromene(10), 5-dehydroxylupinifolin(11), 2-[{2'-(1-hydroxy-1-methylethyl)-7'-(3-methyl-2-butenyl)-2',3'-dihydrobenzofuran}-5'-yl]-7-hydroxy-8-(3-methyl-2-butenyl)chroman-4-one(12), ebenosin(13), and wighteone(14). Among them, compounds 1 and 2 were identified as new compounds, the ~(13)C-NMR data of compounds 3 and 4 were reported for the first time, and compounds 5 and 9 were isolated from this plant for the first time. The MTT assay was used to evaluate the cytotoxic activities of the isolates, and compounds 4, 7, and 10 exhibited significant potent cytotoxic activities on HCT116 cells, with IC_(50) values ranging from 11.44 to 13.43 μmol·L~(-1), comparable with the positive control 5-fluorouracil(5-FU, IC_(50) value is 11.70 μmol·L~(-1)).

PMID 42543360
阅读全文 →
PubMedChemical communications (Cambridge, England)2026-08-03

Photochemical synthesis of 2-phenylquinazolin-4(3H)-ones via the reaction of acylsilanes with 2-cyano-anilines.

Banavath Shireesha S, Dharavath Praveen P, Grée René R, Das Saibal S

Herein, we report a visible-light-mediated, transition-metal-free strategy for the synthesis of E-configured bi-aryl imines and 2-phenylquinazolin-4(3H)-ones via insertion of siloxycarbenes, generated in situ from acylsilanes, into aniline N-H bonds. This operationally simple C-N bond formation transformation proceeds under mild, oxidant-free conditions and exhibits broad compatibility with both aromatic acylsilanes and diverse 2-cyano-anilines. In addition, under basic conditions, the reaction can further be directed toward the efficient construction of complex quinazolinone frameworks.

PMID 42544773
阅读全文 →
PubMedInternational heart journal2026-08-03

Association between Circulating Interleukin-2 and Clinical Outcomes in Patients with Acute Decompensated Heart Failure.

Wang Chenyu C, Yan Gaoliang G, Qin Yuhan Y, Liu Aixin A et al.

Inflammation plays a critical role in the pathogenesis of acute decompensated heart failure (ADHF), and circulating inflammatory cytokines have been implicated in heart failure pathophysiology and progression. However, their association with clinical outcomes in patients with ADHF remains incompletely understood.A total of 872 patients with ADHF who completed 1 year of follow-up were included. Clinical characteristics and inflammatory cytokine levels were compared between patients with and without major adverse cardiovascular events (MACE). Multivariable Cox regression analyses were performed to identify factors independently associated with 1-year MACE. The incremental prognostic information of IL-2 beyond the established clinical risk factors was assessed using net reclassification improvement (NRI) and integrated discrimination improvement (IDI).Serum interleukin-2 (IL-2) levels were significantly higher in patients with MACE than in those without MACE (0.24 pg/mL versus 0.21 pg/mL, P < 0.05). Multivariable Cox regression showed that log2-transformed IL-2 was independently associated with 1-year MACE (HR = 1.212, 95% CI: 1.080-1.359, P = 0.001). Addition of IL-2 to the established clinical risk model significantly improved NRI (0.245, 95% CI: 0.015-0.370, P = 0.032) and IDI (0.019, 95% CI: 0.002-0.043, P = 0.028) for 1-year MACE. Elevated circulating IL-2 levels were independently associated with adverse 1-year clinical outcomes in patients with ADHF and provided incremental prognostic information beyond conventional risk factors. IL-2 may have potential utility for risk stratification in ADHF.

PMID 42543663
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多travoprost